Introduction
The Notch pathway is a highly conserved signaling system that controls cell-fate determination. Recently Notch has been shown to control endothelial cell (EC) proliferation, motility, filopodia formation, adhesion and vessel stabilization 1, 2 . Among the Notch receptors, the endothelium expresses mainly Notch1 and Notch4, which are activated by Delta-like or Jagged family ligands presented in trans by the neighboring . Interestingly, Dll4 inhibitors produced excessive angiogenesis also in tumors, but the perfusion of the newly formed vessels was compromised and thus tumor growth was retarded. [3] [4] [5] Lymphatic vessels are critical for the maintenance of tissue fluid balance, immune responses, and absorption of hydrophobic nutrients in the gut. 6 Lymphangiogenesis, the growth of new lymphatic vessels, is an essential process during embryonic development. 6, 7 Though usually quiescent in adults, lymphatic vessels can sprout from pre-existing vessels and anastomose to form new vessels in pathological conditions, such as inflammation and tumor progression, where production of lymphangiogenic factors is induced. Vascular endothelial growth factor-C (VEGF-C) and VEGF-D,
For personal use only. on . by guest www.bloodjournal.org From 4 acting through VEGF receptor 3 (VEGFR-3), are key inducers of lymphangiogenesis. 6 Loss of Vegfc leads to complete aplasia of the lymphatic vessels and embryonic lethality due to edema, 8 whereas VEGF-D is dispensable for lymphatic development in mice. 6, 9 VEGF-C and VEGF-D are also capable of activating VEGFR-2 following proteolytic processing in the extracellular space. 6 Although VEGFR-3 signals are sufficient for inducing lymphangiogenesis, 10 VEGFR-2, the key receptor driving angiogenesis, is also expressed in the lymphatic endothelium and signaling via this receptor induces circumferential hyperplasia, but not sprouting of lymphatic vessels in vivo, as assessed by adenoviral expression of human or murine VEGF, or a VEGFR-2-specific ligand,
VEGF-E, derived from the Orf virus. [11] [12] [13] VEGF, the major ligand for VEGFR-2, is critical for angiogenesis, 14, 15 but its role in physiological and pathological lymphangiogenesis is not well understood.
Heterozygous loss of Vegf or homozygous inactivation of Vegfr2 leads to death of mice at around embryonic day (E) 8.5 due to failure to form blood vessels. [14] [15] [16] As the lymphatic vessels begin to develop considerably later, at around E10.5, the contribution of the VEGF/VEGFR-2 signaling pathway to lymphatic vessel development has not been addressed by direct gene-targeting studies. 6 Overexpression of VEGF was shown to promote peritumoral lymphangiogenesis and metastasis to distal lymph nodes, 17, 18 but blocking VEGFR-2 in a prostate tumor model, although inhibiting tumor growth
For personal use only. on . by guest www.bloodjournal.org From 5 and angiogenesis, failed to suppress lymph node metastasis. 19 Nevertheless, combinational silencing of both VEGF-C and VEGF showed synergistic benefit in blocking lymph node and lung metastases. 20 However, it is noteworthy that VEGF can recruit VEGFR-1 positive macrophages that produce VEGF-C and VEGF-D, 21 Immunoprecipitation (IP) and Western Blotting. Cells were lysed in RIPA buffer (150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, 1 µg/mL aprotinin, 1µg/mL leupeptin, 1 mM NaF, 1 mM NaVO 4 , 1 mM PMSF). Cell lysates were separated by SDS-PAGE, transferred to PVDF membranes and incubated with antibodies directed against cleaved Notch1 intracellular domain (cNICD, Cell Signaling), VEGFR-2 (R&D), VEGFR-3 (Millipore), phospho-Akt (Cell Signaling), phospho-Erk1/2 (Cell Signaling), phospho-tyrosine (Upstate), Prox-1 (R&D), HSC70 (Santa Cruz) or beta-actin (Cell Signaling), followed by appropriate HRP-conjugated secondary antibodies. For IP, cell lysates were incubated with VEGFR-2 antibody (R&D) overnight and 1 h with protein G Sepharose (GE Healthcare) at +4°C, and subjected to Western Blot analysis as described above. 3-dimensional (3D) bead sprouting assay. Cytodex 3 microcarrier beads (GE Healthcare) were coated with endothelial cells (mixed at 400 cells per bead) in Microvascular Endothelial Cell Growth Medium-2 MV (Lonza), and embedded in 2 mg/ml fibrin gels in 48-well plates by mixing 2 mg/ml fibrinogen (Calbiochem) in Hank's Balanced Salt Solution, 1 U/ml thrombin (Sigma), and 150 µg/ml aprotinin (Sigma). Endothelial Cell Growth Medium-2 (Lonza) containing WI-38 cells (11 000 per well) was added to each well in the presence of human VEGF-C (VEGF-C, 100 ng/ml), Dll4-Fc or HSA conditioned medium, Compound X (30 mM), 23 VEGFR-2 blocking antibody (7 μ g/ml, Imclone), VEGFR1-Fc 24 (7 µg/ml), VEGFR3-Fc, 24 VEGFR-3 blocking antibody (3C5, 10 µg/mL, Imclone), human IgG (7 µg/ml, 10 µg/mL or 20 µg/mL, Sigma), purified Dll4-Fc (20 µg/mL) or their indicated combinations. The cultures were maintained for 6-9 days by changing the medium every other day before fixation with 4% paraformaldehyde (PFA) for 1 h at room temperature (RT). Bright field images were captured with Axiovert 200 (Zeiss) at 5x 
Quantitative PCR (qPCR) analysis. LECs were treated, as indicated in the figure

Blocking Notch promotes LEC sprouting in vitro.
To study if endogenous Notch signals are involved in inhibiting LEC sprouting, as has been demonstrated for BECs, we applied Dll4-Fc to LEC-coated beads embedded in 3D fibrin gels that were covered by WI-38 human fibroblasts in the presence or absence of VEGF-C ( Figure 2A ). Conditioned medium containing Dll4-Fc or purified protein stimulated robust sprouting of the LECs, whereas beads stimulated with the control medium or hIgG did not form sprouts (Figure 2A ,B). Compound X, a gamma-secretase inhibitor that inhibits Notch signaling, 23 also induced LEC sprouting ( Figure 2C ).
Taken together, these results indicate an important role for Notch signaling in the regulation of lymphatic sprouting.
Notch blockade enhances lymphatic sprouting induced by VEGF.
Since VEGF is an integral component of the medium in the bead-sprouting assay, and the co-cultured fibroblasts also produce various growth factors, we resorted to an EC spheroid-sprouting assay, which does not require co-culture of fibroblasts, and allows the titration of VEGF and VEGF-C. As shown in Figure 3A ,C, inhibition of Notch by Dll4-Fc synergized with VEGF in inducing lymphatic sprouting in a dose dependent
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 13 fashion, whereas VEGF alone was less effective. Although Dll4-Fc also increased the sprouting induced by low concentration of VEGF-C (10 ng/ml), this effect was lost when the concentration of VEGF-C increased to 50 ng/ml ( Figure 3B,D) . Taken together, these data suggest that Notch signaling inhibits VEGF-induced lymphatic sprouting, whereas VEGF-C can override this restriction at sufficient doses.
Dll4-Fc potentiates VEGF-induced lymphangiogenesis in vivo.
In order to assess the concomitant effects of Notch inhibition and VEGF or VEGF-C stimulation in vivo, we injected rAAVs encoding Dll4-Fc, VEGF, VEGF-C or HSA 
Role of VEGFR-2 and VEGFR-3 signaling in lymphangiogenesis induced by
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Notch inhibition.
As LECs express both VEGFR-3 and VEGFR-2, which can both stimulate lymphangiogenesis, 6 we wondered if the sprouting induced by Notch blockade is dependent on the activation of these receptors. In the bead-sprouting assay, where 
Regulation of VEGFR-2, VEGFR-3 and ephrinB2 signaling by Notch signaling in
LECs. To dissect the mechanism of how Notch signaling regulates lymphatic sprouting, we determined the expression levels of VEGFR-2 and VEGFR-3. Neither VEGFR-2 nor VEGFR-3 expression at the mRNA or protein level was significantly altered by Figure 2A-C) . Furthermore, the phosphorylation of VEGFR-2 stimulated by VEGF was not affected by Dll4-Fc treatment (Supplemental Figure 2D) . The serine-threonine kinase Akt is known to regulate EC migration and angiogenesis, 25 and Akt is phosphorylated upon VEGF and VEGF-C stimulation in LECs. 26 We therefore asked Figure 3C ).
In BECs, ephrinB2 has been shown to be a target of Notch signaling and involved in EC sprouting, 27 we therefore asked whether ephrinB2 was also regulated by Notch in LECs and accounted for the LEC sprouting induced by Notch inhibition. Indeed, ephrinB2
expression was suppressed by Dll4-Fc, both at the basal level and in the presence of VEGF (Supplemental Figure 4A) . However, blocking the interaction between ephrinB2 and EphB4 using a blocking peptide, did not enhance LEC sprouting induced by VEGF or VEGF-C, but rather inhibited the sprouting (Supplemental Figure 4B ,C).
For
Inhibition of Notch signaling does not affect Prox1 expression in adult mouse tissues or in vitro.
Prox1 is a master regulator of lymphatic development, whose deficiency results in failure of lymphatic vessel formation. 30 We studied Prox1 expression in our in vivo model, as it was recently suggested that overactivation of the Notch signaling pathway can suppress Prox1 expression in cultured LECs. 31 We found that inhibiting Notch by Dll4-Fc did not affect Prox1 expression in adult lymphatic vessels (Supplemental Figure 5A and B), nor did it alter Prox1 expression in cultured LECs (Supplemental Figure 5C ).
Notch signaling regulates tip-stalk specification in LECs.
In vitro and in vivo studies have shown that Notch is cell autonomously required for stalk cell specification in BECs, and that cells with a low degree of Notch signaling and abundant Dll4 expression become selected as tip cells. 28, 29 We therefore hypothesized that the LECs expressing more Dll4 win the competition for the tips. To address this question, a retrovirus expressing Dll4 extracellular and transmembrane domains fused to EGFP (DLL4-ECTM-EGFP, Figure 7A ) was constructed and used to transduce 
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VEGF-C, the percentage of Dll4 positive cells in the tip cell position was significantly higher (increased to 43% and 50% respectively) than expected (30%) (Figure 7B-H 
Discussion
In this study we demonstrate that Notch signaling molecules are expressed at comparable levels in LECs and BECs. Interestingly, inhibition of Notch worked in synergy with VEGF to induce lymphatic sprouting both in vitro and in vivo. The induction of lymphangiogenesis in response to Notch pathway inhibition seems to depend on VEGFR-2 and VEGFR-3 signaling. Furthermore, forced expression of Dll4 in LECs promoted adoption of the tip cell position. These results suggest that the Notch pathway negatively regulates lymphatic sprouting and directs stalk cell specification in LECs.
Role of Notch signaling in LECs
In cultured LECs, the key components of the Notch pathway were expressed at levels comparable to, or even higher than those in BECs, indicating that Notch signaling is important for controlling lymphangiogenesis. Notch1 and Notch4, the two Notch receptors expressed in the vascular endothelium, 1, 2 have been shown to be expressed in lymphatic vessels in normal and tumor tissues, 32 indicating that Notch signaling is active in the lymphatic endothelium in both physiological and pathological conditions.
A number of papers showed that the Notch pathway was important for blood vessel remodeling and ischemia-induced angiogenesis, whereas blockade of Notch signaling resulted in impaired migration, proliferation, and survival of BECs and impaired the recovery of blood flow in response to ischemia. 33, 34 However, the principal role of The role of Notch signaling in LECs is less well understood. A recent study reported that genetic targeting of Notch impaired LEC migration during embryonic development in a zebrafish model. 35 However, results from our mammalian model using adult mice indicated that inhibition of Notch signaling rather induced lymphangiogenesis. This was further supported by 3D in vitro sprouting assays using human LECs subjected to a Notch inhibitor, consistent with the negative role of Notch in regulating the sprouting of the blood vessels. 1 The discrepancy between the study by Geudens et al. and our current work may be explained by the dual function of Notch in inducing cell differentiation and suppressing cell growth, which may be differently regulated in embryonic development and in adults. It is conceivable that, in the embryos, Notch signaling is important for the formation, remodeling or maturation of the lymphatic vasculature, whereas in adults its role is shifted to maintenance of the quiescence of the established vessels. This certainly seems to be the case for blood vessels in adults, as chronic inhibition of Dll4/Notch signaling was recently shown to lead to spontaneous hyperproliferation of BECs and the formation of hemangiomas, 36 and Notch1
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From haploinsufficiency resulted in vascular tumors. 37 In addition, the differences between the endothelial Notch receptors in zebrafish (Notch1b and Notch6), and mammals (Notch1 and Notch4) may also contribute to the discrepancy.
Notch inhibition results in non-productive blood vessels that are poorly perfused. 1 Whether the sprouting lymphatic vessels induced by Notch inhibition are functional remains enigmatic. We and others have previously shown that the lymphatic vessels are poorly functional during sprouting and growth, but they gradually stabilize and become functional within a few months after growth factor stimulation. 38, 39 The lymphatic vessels induced by Dll4-Fc likely undergo a similar course of events.
Interaction between Notch signaling and the VEGF family
Although VEGF potently promotes angiogenesis and sprouting of BECs in vivo, it does not stimulate LEC sprouting, but rather promotes circumferential enlargement of the lymphatic vessels accompanied by LEC proliferation. 11 Here we show that VEGF upregulates Dll4 expression in LECs, which activates Notch to suppress the lymphatic sprouting in response to VEGF. Our gene expression analysis indicated that LECs have a higher baseline expression of several Notch pathway components when compared to BECs. Thus the weaker effects of VEGF on LECs when compared to BECs could be explained by the higher activity of Notch in the LECs at baseline. The VEGF-C/VEGFR-3 pathway also activated Notch signaling in LECs, which seemed to negatively regulate VEGF-C-induced lymphatic sprouting when VEGF-C levels were
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In vivo, combinational treatment with VEGF and Dll4-Fc induced both circumferential enlargement and sprouting of lymphatic vessels, whereas Dll4-Fc did not increase VEGF-C induced sprouting, consistent with the in vitro bead-sprouting assay. Thus, the lymphatic sprouting induced by VEGF-C/VEGFR-3 is essentially unrestrained by Notch, whereas the lymphatic sprouting activity of VEGF/VEGFR-2 is rather weak due to the tight restriction imposed by Notch signaling. This is consistent with the fact that the VEGFR-2 and VEGFR-3 signals in the ECs, although generally overlapping, show some differences. For example in angiogenesis, VEGFR-3 activation seems to potently promote EC migration rather than proliferation. 40, 41 It should also be noted that in the LECs, VEGFR-3 is expressed much more abundantly than VEGFR-2, 42 which may explain why Notch does not restrict VEGFR-3 induced sprouting.
The lymphatic sprouting following Notch inhibition seemed to depend on the VEGF/VEGFR-2 pathway, as Dll4-Fc by itself did not induce sprouting in the spheroid assay of pure LECs, but potentiated VEGF induced sprouting to a similar extent as was achieved by VEGF-C alone. The dependence on VEGF/VEGFR-2 signals was further supported by the fact that both a VEGFR-2 blocking antibody and VEGF trapping by
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VEGFR-1-Fc ablated the Dll4-Fc-induced sprouts both in vivo and in vitro. This is not surprising, given that the increased endothelial filopodia in the developing retinas of Dll4+/-mice were also suppressed by an antibody targeting VEGFR-2 or by soluble VEGFR-1. 43 The requirement for VEGFR-3 is more complicated. Whereas VEGFR-3 is dispensable for Dll4-Fc-induced LEC sprouting in vitro, blocking VEGFR-3 signaling suppressed Dll4-Fc-induced lymphangiogenesis in vivo. The importance of VEGFR-3 signaling for lymphangiogenesis in vivo is evidenced by the fact that activation of VEGFR-2 could not rescue the lymphatic regression caused by prolonged systemic VEGFR3-Fc expression. 11 Importantly, Notch inhibition did not enhance LEC sprouting induced by VEGF-C in any of the assays. Thus, it is possible that in vivo, a low level of VEGF-C or VEGFR-3 activity is required to prime LECs to become responsive to VEGF, e.g. by controlling a critical step in sprout initiation. 44 However in the downstream lymphatic sprouting induced by high dose of VEGF, but not of VEGF-C, is restricted by Notch signaling, as inhibition of Notch signaling enhanced sprouting in response to VEGF, but not to VEGF-C. In our in vivo model of adult mouse ears, inhibition of Notch alone induced lymphangiogenesis. It therefore seems that blocking Notch was able to sensitize the lymphatic endothelium to endogenous growth factor signals emanating from the surrounding microenvironment. Similar endothelial hyperreactivity was observed in certain blood vascular beds of rats and cynomolgus monkeys that were exposed to Notch inhibitors for prolonged periods of time.
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Mechanism of lymphatic sprouting induced by Notch inhibition
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The exact mechanism of how Notch inhibits sprouting has not been fully elucidated. In vivo and in vitro studies show that Notch activation downregulates VEGFR-2 expression in the BECs, thus making them less responsive to VEGF. 1 Although cultured BECs upregulate VEGFR-3 upon NICD overexpression, 32 inhibition of Notch in vivo resulted in widespread VEGFR-3 expression and sprouting of blood vessels. 40 In the LECs, a recent study showed that endothelial overexpression of the Notch1 intracellular domain (N1ICD) upregulated VEGFR-2 expression, whereas the Notch targets Hey1 and Hey2, but not Hes1 or NICD, could downregulate VEGFR-3.
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Another study employing N1ICD overexpression did not report changes in the percentage of LECs positive for VEGFR-3. 32 We observed neither significant alteration in the expression of VEGFR-2 or VEGFR-3, nor in VEGF-induced VEGFR-2 phosphorylation when blocking Notch signaling in LECs. Actually, whereas activation of Notch signaling suppressed VEGFR-2 expression, Notch blockade by gamma-secretase inhibitor did not alter VEGFR-2 levels in cultured BECs. 45 Similarly, in vivo, Notch inhibition failed to increase VEGFR-2 expression in the retinal vessels. Regulation on the transcription factor Prox1, the master gene specifying lymphatic cell 
